Managing BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer (NMIBC): Clinical and Operational Perspectives : Episode 19
Opinion
Video
Navigating Treatment Choices and Financial Considerations in BCG-Unresponsive NMIBC
Author(s):
A panelist discusses how less frequent treatment administration schedules and simpler delivery requirements of newer gene therapies reduce clinic resource burden by minimizing staff time, equipment usage, and biosafety requirements, allowing for more efficient allocation of health care resources.
Video Player is loading.
- How does the ability to administer treatments less frequently, once every 3 months, reduce the resource expenditure in your clinic (eg, staff time and equipment use, allocating more time to patients who need more intensive care or follow-up)?
- Newer gene therapies may not require specialized equipment, such as biosafety hoods, for administration. How does this ease the burden on clinics like yours (such as monotherapy, biosafety, no reconstitution or dilution required)?
Related Videos
Future Directions of BCG-Unresponsive NMIBC Management
Adoption of New Treatments for BCG-Unresponsive NMIBC
BCG-Unresponsive NMIBC: Balancing Care and Financial Considerations
The Impact of Gene Therapy and Advancements in BCG-Unresponsive NMIBC Treatment
Navigating BCG-Unresponsive NMIBC and Emerging Therapies
Enhancing Access to BCG-Unresponsive NMIBC Treatments
Reducing Resource Expenditure in Clinics with New Gene Therapies for BCG-Unresponsive NMIBC
Cost-Effectiveness and Patient Support in Treating BCG-Unresponsive NMIBC
Discussing Treatment Options for BCG-Unresponsive NMIBC
Advancements in BCG-Unresponsive NMIBC and the Impact of Trial Results and Long-Term Follow-Up
Related Content
